---
layout: post
title: "Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments"
date: 2026-02-05 18:36:04 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-06481
original_published: 2023-03-29 00:00:00 +0000
significance: 8.00
---

# Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

**Published:** February 05, 2026 18:36 UTC
**Source:** Federal Register
**Original Published:** March 29, 2023 00:00 UTC
**Document Number:** 2023-06481

## Summary

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pulmonary-Allergy Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/29/2023-06481/pulmonary-allergy-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public-docket)
- API: https://www.federalregister.gov/api/v1/documents/2023-06481

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
